William Blair analyst Matt Phipps initiated coverage of Climb Bio (CLYM) with an Outperform rating and no price target The firm cites the potential of the company’s CD19 antibody, budoprutug, which is being developed across a range of autoimmune indications, for the rating. The simplicity of a monoclonal antibody will be attractive for community physicians who treat most autoimmune patients, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: